Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its autologous ...
Children's Mercy Kansas City has achieved a significant advancement toward the treatment of rare genetic diseases through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback